Trial · NCT00538434
Results by group24
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 24
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Mean Percent Change From Baseline to End of Treatment in Peak Esophageal Eosinophil (EE) Levels | Reslizumab 1 mg/kg | -37.60 | Standard Deviation 70.86 | percentage change in eosinophils/hpf | |
| Mean Percent Change From Baseline to End of Treatment in Peak Esophageal Eosinophil (EE) Levels | Reslizumab 2 mg/kg | -58.27 | Standard Deviation 35.45 | percentage change in eosinophils/hpf | |
| Mean Percent Change From Baseline to End of Treatment in Peak Esophageal Eosinophil (EE) Levels | Reslizumab 3 mg/kg | -56.46 | Standard Deviation 34.82 | percentage change in eosinophils/hpf | |
| Mean Percent Change From Baseline to End of Treatment in Peak Esophageal Eosinophil (EE) Levels | Placebo | 11.50 | Standard Deviation 91.42 | percentage change in eosinophils/hpf | |
| Mean Change From Baseline in Physician's Esophageal Eosinophil (EE) Global Assessment At The End-of-Treatment Visit (or at Early Withdrawal) | Reslizumab 1 mg/kg | -0.85 | Standard Deviation NA | units on a scale | |
| Mean Change From Baseline in Physician's Esophageal Eosinophil (EE) Global Assessment At The End-of-Treatment Visit (or at Early Withdrawal) | Reslizumab 2 mg/kg | -1.02 | Standard Deviation NA | units on a scale | |
| Mean Change From Baseline in Physician's Esophageal Eosinophil (EE) Global Assessment At The End-of-Treatment Visit (or at Early Withdrawal) | Reslizumab 3 mg/kg | -1.12 | Standard Deviation NA | units on a scale | |
| Mean Change From Baseline in Physician's Esophageal Eosinophil (EE) Global Assessment At The End-of-Treatment Visit (or at Early Withdrawal) | Placebo | -1.14 | Standard Deviation NA | units on a scale | |
| Mean Change From Baseline to End of Treatment in EE Predominant Symptom Assessment | Reslizumab 1 mg/kg | -0.94 | Standard Deviation NA | units on a scale | |
| Mean Change From Baseline to End of Treatment in EE Predominant Symptom Assessment | Reslizumab 2 mg/kg | -1.20 | Standard Deviation NA | units on a scale | |
| Mean Change From Baseline to End of Treatment in EE Predominant Symptom Assessment | Reslizumab 3 mg/kg | -1.28 | Standard Deviation NA | units on a scale | |
| Mean Change From Baseline to End of Treatment in EE Predominant Symptom Assessment | Placebo | -1.44 | Standard Deviation NA | units on a scale | |
| Mean Percent Change From Baseline to End of Treatment in the Child Health Questionnaire (CHQ) | Reslizumab 1 mg/kg | Physical Summary Score; n=49, 52, 53, 57 | 11.2 | Standard Deviation NA | percentage change in score |
| Mean Percent Change From Baseline to End of Treatment in the Child Health Questionnaire (CHQ) | Reslizumab 2 mg/kg | Physical Summary Score; n=49, 52, 53, 57 | 18.6 | Standard Deviation NA | percentage change in score |
| Mean Percent Change From Baseline to End of Treatment in the Child Health Questionnaire (CHQ) | Reslizumab 3 mg/kg | Physical Summary Score; n=49, 52, 53, 57 | 18.5 | Standard Deviation NA | percentage change in score |
| Mean Percent Change From Baseline to End of Treatment in the Child Health Questionnaire (CHQ) | Placebo | Physical Summary Score; n=49, 52, 53, 57 | 11.8 | Standard Deviation NA | percentage change in score |
| Mean Percent Change From Baseline to End of Treatment in the Child Health Questionnaire (CHQ) | Reslizumab 1 mg/kg | Psychosocial Summary Score; n=51, 52, 53, 55 | 5.0 | Standard Deviation NA | percentage change in score |
| Mean Percent Change From Baseline to End of Treatment in the Child Health Questionnaire (CHQ) | Reslizumab 2 mg/kg | Psychosocial Summary Score; n=51, 52, 53, 55 | 12.2 | Standard Deviation NA | percentage change in score |
| Mean Percent Change From Baseline to End of Treatment in the Child Health Questionnaire (CHQ) | Reslizumab 3 mg/kg | Psychosocial Summary Score; n=51, 52, 53, 55 | 14.1 | Standard Deviation NA | percentage change in score |
| Mean Percent Change From Baseline to End of Treatment in the Child Health Questionnaire (CHQ) | Placebo | Psychosocial Summary Score; n=51, 52, 53, 55 | 10.1 | Standard Deviation NA | percentage change in score |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00538434/results